J Korean Child Neurol Soc.  2013 Mar;21(1):1-6.

Effectiveness and Tolerability of Fosphenytoin for Pediatric Status Epilepticus

Affiliations
  • 1Pediatric Clinical Neuroscience Center, Department of Pediatrics, Seoul National University Children's hospital, Seoul, Republic of Korea.
  • 2Department of Pediatrics, Seoul National University Bundang Hospital, Gyeonggi-do, Republic of Korea. neuroandy@snubh.org
  • 3Department of Pediatrics, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • 4Department of Pediatrics, SMG-SNU Boramae Medical Center, Seoul, Republic of Korea.

Abstract

PURPOSE
The study was aimed to investigate the effectiveness and tolerability of intravenous fosphenytoin (fPHT) in the treatment of pediatric status epilepticus (SE).
METHODS
Medical-records of patients who received intravenous (IV) fPHT for the treatment of SE were retrospectively reviewed and their clinical data were analyzed regarding age, gender, seizure types, underlying neurologic status, use of other anticonvulsants, loading dose, response and adverse events of IV fPHT.
RESULTS
Twenty patients (12 boys and 8 girls) were included in the study. The mean age at administration of IV fPHT was 3.98 years (range 0-18.6 years). Of the 20 patients, 15 patients had no underlying neurological conditions, but five patients were on anticonvulsants. IV fPHT terminated the seizures in 15 of the 20 patients (75%). No adverse events occurred during or after the infusions.
CONCLUSION
This study demonstrated that IV fPHT was as effective as phenytoin and was well-tolerated in the treatment of pediatric SE. IV fPHT can be considered as a substitute for phenytoin in the management of pediatric SE.

Keyword

Fosphenytoin; Pediatric; Status Epilepticus; Effectiveness; Tolerability

MeSH Terms

Anticonvulsants
Humans
Phenytoin
Retrospective Studies
Seizures
Status Epilepticus
Anticonvulsants
Phenytoin
Full Text Links
  • JKCNS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr